NationDrugs.to introduces a reliable solution for patients searching for affordable and high-quality generic cancer drugs.

Early detection of drug-drug interactions (DDIs) can facilitate timely drug development decisions, prevent unnecessary restrictions on patient enrollment, resulting in clinical study populations that are not representative of the indicated study population, and allow for appropriate dose adjustments to ensure safety in clinical trials. All of these factors contribute to a streamlined drug approval process and enhanced patient safety. Here we describe a new approach for early prediction of the magnitude of change in exposure for cytochrome P450 (P450) CYP3A4-related DDIs of small-molecule anticancer drugs based on the model-based extrapolation of human-CYP3A4-transgenic mice pharmacokinetics to humans. Victim drugs brigatinib and lorlatinib were evaluated with the new approach in combination with the perpetrator drugs itraconazole and rifampicin. Predictions of the magnitude of change in exposure deviated at most 0.99- to 1.31-fold from clinical trial results for inhibition with itraconazole, whereas exposure predictions for the induction with rifampicin were less accurate, with deviations of 0.22- to 0.48-fold. Results for the early prediction of DDIs and their clinical impact appear promising for CYP3A4 inhibition, but validation with more victim and perpetrator drugs is essential to evaluate the performance of the new method.

Men taking either abiraterone or enzalutamide for advanced prostate cancer who had also undergone hormone therapy were at increased risk of serious metabolic

Using cancer drugs in malaria treatment can speed up the discovery process of new life-saving therapies for malaria, which is becoming increasingly drug-resistant.

Advaxis has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on IND applications of its three drugs. Advaxis is

The GST Council, led by Finance Minister Nirmala Sitharaman, has formed a Group of Ministers to evaluate reducing GST rates on life and health insurance,

Govt. had earlier scrapped customs duty on Trastuzumab, Osimertinib and Durvalumab and also reduced GST rates on them

Study shows how stopping one enzyme could help drugs treat an important class of cancers more effectively

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

RETIRED engineer Brian Cramp is a medical pioneer.

A team of Princeton chemists has identified a way to tag a protein's nearest molecular neighbors, enabling the precise mapping of their micro-environment. This could open new avenues to cancer treatment and other drug therapies.

Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did. On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each. That price was the midpoint of the targeted $14 to $16 […]

Hazim Gaber, 22, of Edmonton, Canada, pleaded guilty today in Phoenix before U.S. Magistrate Judge Edward C. Voss to selling counterfeit cancer drugs using the Internet.

Hazim Gaber, 22, of Edmonton, Canada, was sentenced today in Phoenix by U.S. District Court Judge James A. Teilborg to 33 months in prison for selling counterfeit cancer drugs using the Internet.

Structural and biochemical differences among anticancer medications PARP inhibitors were linked to differing capacities to kill cancer cells, according

Chemotherapeutic drugs or antineoplastic agents used to treat various cancers enter the aquatic environment through human excretion and wastewater treatment facilities.

Two hormone treatments used in prostate cancer patients will be available before chemotherapy, as hospitals try to keep patients away from hospitals during the coronavirus crisis.

Study shows how stopping one enzyme could help drugs treat an important class of cancers more effectively